prikaz prve stranice dokumenta Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini
  Download
PDF 732.48 KB
Professional paper - Professional paper
Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini
Farmaceutski glasnik, 78 (2022), 7-8; 337-348. urn:nbn:hr:163:319517
Kanižaj, Lucija; Mirošević Skvrce, Nikica; Ortner Hadžiabdić, Maja; Margan Koletić, Željana; Tomić, Siniša

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Kanižaj, L., Mirošević Skvrce, N., Ortner Hadžiabdić, M., Margan Koletić, Ž. & Tomić, S. (2022). Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini. Farmaceutski glasnik, 78. (7-8), 337-348. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:319517

Kanižaj, Lucija, et al. "Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini." Farmaceutski glasnik, vol. 78, no. 7-8, 2022, pp. 337-348. https://urn.nsk.hr/urn:nbn:hr:163:319517

Kanižaj, Lucija, Nikica Mirošević Skvrce, Maja Ortner Hadžiabdić, Željana Margan Koletić and Siniša Tomić. "Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini." Farmaceutski glasnik 78, no. 7-8 (2022): 337-348. https://urn.nsk.hr/urn:nbn:hr:163:319517

Kanižaj, L., et al. (2022) 'Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini', Farmaceutski glasnik, 78(7-8), pp. 337-348. Available at: https://urn.nsk.hr/urn:nbn:hr:163:319517 (Accessed 25 November 2024)

Kanižaj L, Mirošević Skvrce N, Ortner Hadžiabdić M, Margan Koletić Ž, Tomić S. Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini. Farmaceutski glasnik [Internet]. 2022 [cited 2024 November 25];78(7-8):337-348. Available at: https://urn.nsk.hr/urn:nbn:hr:163:319517

L. Kanižaj, N. Mirošević Skvrce, M. Ortner Hadžiabdić, Ž. Margan Koletić and S. Tomić, "Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini", Farmaceutski glasnik, vol. 78, no. 7-8, pp. 337-348, 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:319517. [Accessed: 25 November 2024]

Metadata
Title (croatian)Analiza sigurnosnog profila TNF-a inhibitora na temelju zaprimljenih prijava sumnji na nuspojave u 2018. i 2019. godini
AuthorLucija Kanižaj
AuthorNikica Mirošević Skvrce
AuthorMaja Ortner Hadžiabdić
AuthorŽeljana Margan Koletić
AuthorSiniša Tomić
Author's institutionUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Centre for applied pharmacy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract (english)
The aim of this study was to analyze the adverse drug reactions of TNF-a inhibitors reported to the Agency for Medicina! Products and Medica! Devices of Croatia in the period from 1 January 2018 to 31 December 2019, and to raise awareness of the safety profile of these drugs and risk minimization measures, especially additional measures. Reports of suspected adverse reactions were analyzed according to: reporter qualification, age and sex of the patient, suspected drug, concomitant drugs, seriousness of reaction, System Organ Class using the Medical Dictionary for Drug Regulatory Affairs (MedDRA). Total of 246 ADR (Adverse drug reaction) reports were analyzed. Majority of patients belonged to the age group 45-64 years (39.4 %) and were female (60.6 %). ADRs were in most cases reported by physicians (86.2 %). The most frequent suspected active substances were infliximab and adalimumab, while concomitant substances the most often belonged to the group of immunosuppressants and analgesics. Of all received ADR reports, 61 % were serious. Majority of ADRs belonged to System Organ Class "General disorders and administration site conditions" and the most commonly reported preferred tem was "drug ineffectiveness''. The obtained results can improve prevention, detection and treatment of possible adverse reactions.
Keywords (croatian)
Languagecroatian
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review - domestic
Publication versionPublished version
Journal titleFarmaceutski glasnik
Numberingvol. 78, no. 7-8, pp. 337-348
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:319517
Publication2022
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-09-07 15:48:27